Demographics, Outcomes, and Clinical Characteristics in All Included Patients and in Those Who Developed Thyroid Dysfunction
| Demographics . | All Patients (n = 484) . | Patients Who Developed Thyroid Dysfunction (n = 63) . |
|---|---|---|
| Sex, n (%) | ||
| Male | 300 (62) | 42 (66.7) |
| Race groups, n (%) | ||
| Black | 106 (22) | 13 (20.6) |
| White | 261 (54) | 28 (44.4) |
| Other | 110 (22.7) | 22 (34.9) |
| Unknown | 7 (1.4) | |
| Ethnicity, n (%) | ||
| Latino | 52 (10.7) | 8 (14.8) |
| Age, median (IQR) | 1.35 (1.4–15.1) | |
| Age started amiodarone, median (IQR) | n/a | 0.7 (0.1–10.4) |
| Died, n (%) | n/a | 14 (22.2) |
| Thyroid outcome, n (%) | ||
| Hyperthyroidism | 4 (6.4) | |
| Hypothyroidism | 26 (41.3) | |
| Subclinical hypothyroidism | 33 (53.3) | |
| Days on amiodarone before developing thyroid dysfunction, median (IQR) | 9 (3–20) | |
| Resolved, n (%) | 29 (49.2) |
| Demographics . | All Patients (n = 484) . | Patients Who Developed Thyroid Dysfunction (n = 63) . |
|---|---|---|
| Sex, n (%) | ||
| Male | 300 (62) | 42 (66.7) |
| Race groups, n (%) | ||
| Black | 106 (22) | 13 (20.6) |
| White | 261 (54) | 28 (44.4) |
| Other | 110 (22.7) | 22 (34.9) |
| Unknown | 7 (1.4) | |
| Ethnicity, n (%) | ||
| Latino | 52 (10.7) | 8 (14.8) |
| Age, median (IQR) | 1.35 (1.4–15.1) | |
| Age started amiodarone, median (IQR) | n/a | 0.7 (0.1–10.4) |
| Died, n (%) | n/a | 14 (22.2) |
| Thyroid outcome, n (%) | ||
| Hyperthyroidism | 4 (6.4) | |
| Hypothyroidism | 26 (41.3) | |
| Subclinical hypothyroidism | 33 (53.3) | |
| Days on amiodarone before developing thyroid dysfunction, median (IQR) | 9 (3–20) | |
| Resolved, n (%) | 29 (49.2) |
Abbreviations: IQR, interquartile range; n/a, not applicable.
Demographics, Outcomes, and Clinical Characteristics in All Included Patients and in Those Who Developed Thyroid Dysfunction
| Demographics . | All Patients (n = 484) . | Patients Who Developed Thyroid Dysfunction (n = 63) . |
|---|---|---|
| Sex, n (%) | ||
| Male | 300 (62) | 42 (66.7) |
| Race groups, n (%) | ||
| Black | 106 (22) | 13 (20.6) |
| White | 261 (54) | 28 (44.4) |
| Other | 110 (22.7) | 22 (34.9) |
| Unknown | 7 (1.4) | |
| Ethnicity, n (%) | ||
| Latino | 52 (10.7) | 8 (14.8) |
| Age, median (IQR) | 1.35 (1.4–15.1) | |
| Age started amiodarone, median (IQR) | n/a | 0.7 (0.1–10.4) |
| Died, n (%) | n/a | 14 (22.2) |
| Thyroid outcome, n (%) | ||
| Hyperthyroidism | 4 (6.4) | |
| Hypothyroidism | 26 (41.3) | |
| Subclinical hypothyroidism | 33 (53.3) | |
| Days on amiodarone before developing thyroid dysfunction, median (IQR) | 9 (3–20) | |
| Resolved, n (%) | 29 (49.2) |
| Demographics . | All Patients (n = 484) . | Patients Who Developed Thyroid Dysfunction (n = 63) . |
|---|---|---|
| Sex, n (%) | ||
| Male | 300 (62) | 42 (66.7) |
| Race groups, n (%) | ||
| Black | 106 (22) | 13 (20.6) |
| White | 261 (54) | 28 (44.4) |
| Other | 110 (22.7) | 22 (34.9) |
| Unknown | 7 (1.4) | |
| Ethnicity, n (%) | ||
| Latino | 52 (10.7) | 8 (14.8) |
| Age, median (IQR) | 1.35 (1.4–15.1) | |
| Age started amiodarone, median (IQR) | n/a | 0.7 (0.1–10.4) |
| Died, n (%) | n/a | 14 (22.2) |
| Thyroid outcome, n (%) | ||
| Hyperthyroidism | 4 (6.4) | |
| Hypothyroidism | 26 (41.3) | |
| Subclinical hypothyroidism | 33 (53.3) | |
| Days on amiodarone before developing thyroid dysfunction, median (IQR) | 9 (3–20) | |
| Resolved, n (%) | 29 (49.2) |
Abbreviations: IQR, interquartile range; n/a, not applicable.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
